Item 2.01.
|
Completion of Acquisition or Disposition of Assets.
|
On November 18,
2020 (the “Closing Date”), Liquidia Technologies, Inc., a Delaware corporation (“Liquidia Technologies”),
completed the previously announced acquisition contemplated by the Agreement and Plan of Merger, dated as of June 29, 2019, as
amended by a Limited Waiver and Modification to the Merger Agreement, dated as of August 3, 2020 (the “Merger Agreement”),
by and among Liquidia Technologies, Liquidia Corporation (“Liquidia Corporation” and, together with Liquidia Corporation,
“Liquidia”), RareGen, LLC, a Delaware limited liability company (“RareGen”), Gemini Merger Sub I, Inc.,
a Delaware corporation (“Liquidia Merger Sub”), Gemini Merger Sub II, LLC, a Delaware limited liability company (“RareGen
Merger Sub”), and PBM RG Holdings, LLC, a Delaware limited liability company, as Members’ Representative. Pursuant
to the Merger Agreement, Liquidia Merger Sub, a wholly owned subsidiary of Liquidia Corporation, merged with and into Liquidia
Technologies (the “Liquidia Technologies Merger”), and RareGen Merger Sub, a wholly owned subsidiary of Liquidia Corporation,
merged with and into RareGen (the “RareGen Merger” and, together with the Liquidia Technologies Merger, the “Merger
Transaction”). Upon consummation of the Merger Transaction, the separate corporate existences of Liquidia Merger Sub and
RareGen Merger Sub ceased and Liquidia Technologies and RareGen continue as wholly owned subsidiaries of Liquidia Corporation.
Liquidia Technologies Merger
Upon completion
of the Liquidia Technologies Merger, each outstanding share of common stock, $0.001 par value per share, of Liquidia Technologies
(“Liquidia Technologies Common Stock”), whether certificated or held in book-entry form, automatically converted into
one share of Liquidia Corporation Common Stock, and such shares of Liquidia Technologies Common Stock converted into Liquidia Corporation
Common Stock were cancelled. In addition, (i) each outstanding option and warrant to purchase shares of Liquidia Technologies Common
Stock was assumed by Liquidia Corporation and represents the right to purchase a like number of shares of Liquidia Corporation
Common Stock on the same terms and conditions, including vesting and exercise price per share, then-applicable to such Liquidia
Technologies option or warrant, as applicable, and (ii) each outstanding restricted stock unit to acquire shares of Liquidia Technologies
Common Stock was assumed by Liquidia Corporation and represents the right to acquire a like number of shares of Liquidia Corporation
Common Stock on the same terms and conditions, including vesting, then-applicable to such Liquidia Technologies restricted stock
unit.
Consideration to RareGen
On the Closing
Date, RareGen members received an aggregate of 5,550,000 shares of Liquidia Corporation Common Stock. Furthermore, on the Closing
Date 616,666 shares of Liquidia Corporation Common Stock (the “Holdback Shares”) were withheld from RareGen members
to secure the indemnification obligations of RareGen members, as further described below. As previously disclosed, RareGen members
are also entitled to receive up to an aggregate of 2,708,333 shares of Liquidia Corporation Common Stock (the “Net Sales
Earnout Shares”), based on the amount of 2021 net sales of the first-to-file substitutable generic treprostinil injection
for the treatment of patients with pulmonary arterial hypertension (PAH) in the United States, pursuant to that certain Promotion
Agreement, dated as of August 1, 2018, as amended, between RareGen and Sandoz Inc.
The Holdback Shares
may be reduced by: (i) the portion of the Holdback Shares, if any, used to satisfy the obligations of the RareGen members to the
Liquidia indemnitees in accordance with Article 7 of the Merger Agreement; and (ii) the portion of the Holdback Shares, if any,
to the extent reasonably necessary to serve as security for any unresolved or unsatisfied claims for losses incurred by an indemnified
party (the “Reserve Shares”). The Holdback Shares remaining after giving effect to the reductions set forth in clauses
(i) and (ii) in the immediately preceding sentence are referred to in the Merger Agreement as the “Remaining Holdback Shares.”
The Remaining Holdback Shares shall be disbursed to Computershare Trust Company, N.A. (the “Exchange Agent”) for the
benefit of the RareGen members, on March 31, 2022, and the Reserve Shares shall be disbursed to the Exchange Agent, for the benefit
of the RareGen members upon the final resolution of any unresolved claim to which such Reserve Shares were subject.
Form S-4 and Merger Agreement
The issuance of
shares of Liquidia Corporation Common Stock in connection with the Merger Transaction, as described above, was registered under
the Securities Act of 1933, as amended, pursuant to a registration statement on Form S-4 (File No. 333-240421), filed
by Liquidia Corporation with the Securities and Exchange Commission (the “SEC”) and declared effective on September
16, 2020 (the “Registration Statement”). The proxy statement/prospectus of Liquidia Technologies and Liquidia Corporation
(the “Proxy Statement/Prospectus”) included in the Registration Statement, as supplemented on October 8, 2020 and November 5, 2020, contains additional information about the Merger Transaction and the related transactions. The description of Liquidia
Corporation Common Stock set forth in the Proxy Statement/Prospectus is incorporated herein by reference. Additional information
about the Merger Transaction is also contained in Current Reports on Form 8-K filed by Liquidia Technologies on January 27, 2020, March 20, 2020, March 30, 2020, April 8, 2020, April 13, 2020, April 30, 2020, May 18, 2020, June 5, 2020, June 19, 2020,
June 29, 2020, July 2, 2020, July 24, 2020, August 20, 2020, October 14, 2020, October 19, 2020 and November 2, 2020 and incorporated
by reference into the Proxy Statement/Prospectus.
The description
of the Merger Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the Merger
Agreement, a copy of which is filed as Exhibit 2.1 and 2.2 hereto and is incorporated herein by reference. This summary is
not intended to modify or supplement any factual disclosures about Liquidia Corporation, Liquidia Technologies or RareGen,
and should not be relied upon as disclosure about Liquidia Corporation, Liquidia Technologies or RareGen without consideration
of the periodic and current reports and statements that Liquidia Corporation and Liquidia Technologies file with the SEC. The terms
of the Merger Agreement govern the contractual rights and relationships, and allocate risks, among the parties in relation to the
transactions contemplated by the Merger Agreement. In particular, the representations and warranties made by the parties to each
other in the Merger Agreement reflect negotiations between, and are solely for the benefit of, the parties thereto and may be limited
or modified by a variety of factors, including: subsequent events, information included in public filings, disclosures made during
negotiations, correspondence between the parties and disclosure schedules to the Merger Agreement. Accordingly, the representations
and warranties may not describe the actual state of affairs at the date they were made or at any other time and you should not
rely on them as statements of fact.